91
Views
11
CrossRef citations to date
0
Altmetric
Original Research

Prognostic analysis of patients with mutant and wild-type EGFR gene lung adenocarcinoma

, , , , , , , & show all
Pages 6139-6150 | Published online: 04 Jul 2019

References

  • Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67:7–30. doi:10.3322/caac.2138728055103
  • Hecht SS. Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer. 2003;3(10):733–744. doi:10.1038/nrc119014570033
  • Wogan GN, Hecht SS, Felton JS, Conney AH, Loeb LA. Environmental and chemical carcinogenesis. Semin Cancer Biol. 2004;14(6):473–486. doi:10.1016/j.semcancer.2004.06.01015489140
  • Thun MJ, Henley SJ, Calle EE. Tobacco use and cancer: an epidemiologic perspective for geneticists. Oncogene. 2002;21(48):7307–7325. doi:10.1038/sj.onc.120580712379875
  • Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–181. doi:10.1038/nrc208817318210
  • Steuer CE, Ramalingam SS. Targeting EGFR in lung cancer: lessons learned and future perspectives. Mol Aspects Med. 2015;45:67–73. doi:10.1016/j.mam.2015.05.00426022942
  • Wang H, Zhang M, Tang W, et al. Mutation abundance affects the therapeutic efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma: a retrospective analysis. Cancer Biol Ther. 2018;19(8):687–694.
  • Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350(21):2129–2139. doi:10.1056/NEJMoa04093815118073
  • Sun PL, Seol H, Lee HJ, et al. High incidence of EGFR mutations in Korean men smokers with no intratumoral heterogeneity of lung adenocarcinomas: correlation with histologic subtypes, EGFR/TTF-1 expressions, and clinical features. J Thorac Oncol. 2012;7(2):323–330. doi:10.1097/JTO.0b013e318238151522237264
  • Wang T, Zhang Y, Liu B, Hu M, Zhou N, Zhi X. Associations between epidermal growth factor receptor mutations and histological subtypes of lung adenocarcinoma according to the IASLC/ATS/ERS classification in Chinese patients. Thorac Cancer. 2017;8(6):600–605. doi:10.1111/1759-7714.1248928940943
  • Ninomiya H, Hiramatsu M, Inamura K, et al. Correlation between morphology and EGFR mutations in lung adenocarcinomas significance of the micropapillary pattern and the hobnail cell type. Lung Cancer. 2009;63(2):235–240. doi:10.1016/j.lungcan.2008.04.01718571764
  • Clay TD, Russell PA, Do H, et al. Associations between the IASLC/ATS/ERS lung adenocarcinoma classification and EGFR and KRAS mutations. Pathology. 2016;48(1):17–24. doi:10.1016/j.pathol.2015.11.00227020204
  • Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The Eighth edition lung cancer stage classification. Chest. 2017;151(1):193–203. doi:10.1016/j.chest.2016.10.01027780786
  • Travis WD, Brambilla E, Noguchi M, et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma. J Thorac Oncol. 2011;6(2):244–285. doi:10.1097/JTO.0b013e318206a22121252716
  • Yoshida T, Ishii G, Goto K, et al. Solid predominant histology predicts EGFR tyrosine kinase inhibitor response in patients with EGFR mutation-positive lung adenocarcinoma. J Cancer Res Clin Oncol. 2013;139(10):1691–1700. doi:10.1007/s00432-013-1495-023974272
  • Li L, Zhang Z, Bie Z, et al. Epidermal growth factor receptor mutation analysis in cytological specimens and responsiveness to gefitinib in advanced non-small cell lung cancer patients. Chin J Cancer Res. 2015;27:294–300.26157326
  • Hata A, Katakami N, Yoshioka H, et al. Spatiotemporal T790M heterogeneity in individual patients with EGFR-Mutant non-small-cell lung cancer after acquired resistance to EGFR-TKI. J Thorac Oncol. 2015;10(11):1553–1559. doi:10.1097/JTO.000000000000064726309190
  • Hsieh RK, Lim KH, Kuo HT, Tzen CY, Huang MJ. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest. 2005;128(1):317–321. doi:10.1378/chest.128.1.31716002952
  • Zhuo M, Zheng Q, Zhao J, et al. Survival difference between EGFR Del19 and L858R mutant advanced non-small cell lung cancer patients receiving gefitinib: a propensity score matching analysis. Chin J Cancer Res. 2017;29(6):553–560. doi:10.21147/j.issn.1000-9604.2017.06.1029353978
  • Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst. 2005;97:643–655. doi:10.1093/jnci/dji08015870435